Cargando…

Performance comparison of aspirin assay between Anysis and VerifyNow: Assessment of therapeutic platelet inhibition in patients with cardiac diseases

BACKGROUND: Assessment of platelet inhibition for aspirin therapy is important to manage patients who are at potential risk of developing thrombotic and hemorrhagic complications. OBJECTIVE: This study aimed to evaluate a new platelet assay (Anysis-aspirin), compare it with VerifyNow-aspirin in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Piao, Jinxiang, Yoo, Chaeyoung, Kim, SeonYoung, Whang, Youn-Wha, Choi, Cheol Ung, Shin, Sehyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673509/
https://www.ncbi.nlm.nih.gov/pubmed/33967038
http://dx.doi.org/10.3233/CH-211171
_version_ 1784615466232184832
author Piao, Jinxiang
Yoo, Chaeyoung
Kim, SeonYoung
Whang, Youn-Wha
Choi, Cheol Ung
Shin, Sehyun
author_facet Piao, Jinxiang
Yoo, Chaeyoung
Kim, SeonYoung
Whang, Youn-Wha
Choi, Cheol Ung
Shin, Sehyun
author_sort Piao, Jinxiang
collection PubMed
description BACKGROUND: Assessment of platelet inhibition for aspirin therapy is important to manage patients who are at potential risk of developing thrombotic and hemorrhagic complications. OBJECTIVE: This study aimed to evaluate a new platelet assay (Anysis-aspirin), compare it with VerifyNow-aspirin in patients with cardiac diseases, and analyze the aspirin resistance rates between the two devices. METHODS: Citrated blood samples were collected from patients with cardiac diseases referred for the aspirin response test. In the Anysis assay, a test result was provided with a blood flow migration distance (MD) until blood flow stoppage, which was comparable to aspirin reaction units (ARUs) obtained using VerifyNow. The measurements were simultaneously conducted using the two devices and compared. RESULTS: The MD without and with aspirin use was 160±33 and 254±23 mm, respectively (p < 0.0001). Compared with VerifyNow (reference), the sensitivity and specificity of Anysis-200 were 96.3 and 90.3%, respectively (area under the curve, 0.968). Furthermore, the aspirin resistance rate in aspirin-administered patients was 20.9%using VerifyNow and 16.5%for Anysis-200. The Cohen’s kappa coefficient between the two devices was 0.81, indicating an almost perfect agreement between the two devices. CONCLUSIONS: Anysis-aspirin, a novel aspirin assay for assessing platelet inhibition, showed excellent agreement with VerifyNow-aspirin with high accuracy and precision. The Anysis-aspirin assay would be used as a point-of-care test to assess aspirin non-responsiveness and abnormal platelet reactivity.
format Online
Article
Text
id pubmed-8673509
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-86735092021-12-29 Performance comparison of aspirin assay between Anysis and VerifyNow: Assessment of therapeutic platelet inhibition in patients with cardiac diseases Piao, Jinxiang Yoo, Chaeyoung Kim, SeonYoung Whang, Youn-Wha Choi, Cheol Ung Shin, Sehyun Clin Hemorheol Microcirc Research Article BACKGROUND: Assessment of platelet inhibition for aspirin therapy is important to manage patients who are at potential risk of developing thrombotic and hemorrhagic complications. OBJECTIVE: This study aimed to evaluate a new platelet assay (Anysis-aspirin), compare it with VerifyNow-aspirin in patients with cardiac diseases, and analyze the aspirin resistance rates between the two devices. METHODS: Citrated blood samples were collected from patients with cardiac diseases referred for the aspirin response test. In the Anysis assay, a test result was provided with a blood flow migration distance (MD) until blood flow stoppage, which was comparable to aspirin reaction units (ARUs) obtained using VerifyNow. The measurements were simultaneously conducted using the two devices and compared. RESULTS: The MD without and with aspirin use was 160±33 and 254±23 mm, respectively (p < 0.0001). Compared with VerifyNow (reference), the sensitivity and specificity of Anysis-200 were 96.3 and 90.3%, respectively (area under the curve, 0.968). Furthermore, the aspirin resistance rate in aspirin-administered patients was 20.9%using VerifyNow and 16.5%for Anysis-200. The Cohen’s kappa coefficient between the two devices was 0.81, indicating an almost perfect agreement between the two devices. CONCLUSIONS: Anysis-aspirin, a novel aspirin assay for assessing platelet inhibition, showed excellent agreement with VerifyNow-aspirin with high accuracy and precision. The Anysis-aspirin assay would be used as a point-of-care test to assess aspirin non-responsiveness and abnormal platelet reactivity. IOS Press 2021-11-11 /pmc/articles/PMC8673509/ /pubmed/33967038 http://dx.doi.org/10.3233/CH-211171 Text en © 2021 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Piao, Jinxiang
Yoo, Chaeyoung
Kim, SeonYoung
Whang, Youn-Wha
Choi, Cheol Ung
Shin, Sehyun
Performance comparison of aspirin assay between Anysis and VerifyNow: Assessment of therapeutic platelet inhibition in patients with cardiac diseases
title Performance comparison of aspirin assay between Anysis and VerifyNow: Assessment of therapeutic platelet inhibition in patients with cardiac diseases
title_full Performance comparison of aspirin assay between Anysis and VerifyNow: Assessment of therapeutic platelet inhibition in patients with cardiac diseases
title_fullStr Performance comparison of aspirin assay between Anysis and VerifyNow: Assessment of therapeutic platelet inhibition in patients with cardiac diseases
title_full_unstemmed Performance comparison of aspirin assay between Anysis and VerifyNow: Assessment of therapeutic platelet inhibition in patients with cardiac diseases
title_short Performance comparison of aspirin assay between Anysis and VerifyNow: Assessment of therapeutic platelet inhibition in patients with cardiac diseases
title_sort performance comparison of aspirin assay between anysis and verifynow: assessment of therapeutic platelet inhibition in patients with cardiac diseases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673509/
https://www.ncbi.nlm.nih.gov/pubmed/33967038
http://dx.doi.org/10.3233/CH-211171
work_keys_str_mv AT piaojinxiang performancecomparisonofaspirinassaybetweenanysisandverifynowassessmentoftherapeuticplateletinhibitioninpatientswithcardiacdiseases
AT yoochaeyoung performancecomparisonofaspirinassaybetweenanysisandverifynowassessmentoftherapeuticplateletinhibitioninpatientswithcardiacdiseases
AT kimseonyoung performancecomparisonofaspirinassaybetweenanysisandverifynowassessmentoftherapeuticplateletinhibitioninpatientswithcardiacdiseases
AT whangyounwha performancecomparisonofaspirinassaybetweenanysisandverifynowassessmentoftherapeuticplateletinhibitioninpatientswithcardiacdiseases
AT choicheolung performancecomparisonofaspirinassaybetweenanysisandverifynowassessmentoftherapeuticplateletinhibitioninpatientswithcardiacdiseases
AT shinsehyun performancecomparisonofaspirinassaybetweenanysisandverifynowassessmentoftherapeuticplateletinhibitioninpatientswithcardiacdiseases